Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BIXLENVO safely and effectively. See full prescribing information for BIXLENVO. BIXLENVO™ (bictegravir and lenacapavir) tablets, for oral use Initial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-prescription
BIXLENVO is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO [see Clinical Studies (14)].
- generic_name
- bictegravir/lenacapavir
- product_names
- bictegravir/lenacapavir
- ndc
- 61958-3601, 61958-3601-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en